The meleumycin produced by Nanyang Pukang Hengyu Pharmaceutical Co, has a wide antibacterial spectrum, an obvious curative effect and comparatively low toxicity and side effects.

The meleumycin was first introduced by the company in 1987. With a total investment worth 32 million yuan ($5.2 million), the production line has undergone five major technological transformations in order to improve the quality of its production, whose annual output has reached 220 tons. As the largest manufacturer of meleumycin, Pukang Hengyu, which has the highest sales-output ratio, lowest costs and the most advanced technological standards in China, has generated considerable economic and social benefits.